References
- DiNicolantonio, J. J., Serebruany, V. L. (2013). Challenging the FDA black box warning for high aspirin dose with cicagrelor in patients with diabetes. Diabetes 62(3):669–671.
- Ezzet, F., Mull, R., Karbwang, J. (1998). Population pharmacokinetics and therapeutic response of CGP 56697 (artemether+benflumetol) in malaria patients. British Journal of Clinical Pharmacology 46(6):553–561.
- Holford, N. H. (1995). The target concentration approach to clinical drug development. Clinical Pharmacokinetics 29(5):287–291.
- Holford, N. H. G. (1999). Target concentration intervention: Beyond T2K. British Journal of Clinical Pharmacology 48(1):9–13.
- Martinez, M. N., Papich, M. G., Drusano, G. L. (2012). Dosing regimen matters: The importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrobial Agents and Chemotherapy 56(6):2795–2805.
- Moore, M. J., Erlichman, C. (1987). Therapeutic drug monitoring in oncology. Clinical Pharmacokinetics 13(4):205–227.
- Novartis, A. (2007). Prexige® receives “not approvable” letter in the US despite being one of the most studied cox-2 inhibitors. Technical report, Media Release, http://hugin.info/134323/R/1156327/223186.pdf.
- Reeve, R. (1996). The randomized concentration-controlled trial: Mathematical definitions, a dose-adjusting algorithm, and sample size efficiency. Communications in Statistics - Theory and Methods 25(9):2169–2188.
- Sanathanan, L. P., Peck, C. C. (1991). The randomized concentration-controlled trial: An evaluation of its sample size efficiency. Controlled Clinical Trials 12(6):780–794.